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Available online 5 January 2017Background: Patients with end-stage renal disease (ESRD) undergoing haemodialysis (HD) experience enhanced
oxidative stress and systemic inﬂammation, which are risk factors for cardiovascular disease, the most common
cause of excess morbidity and mortality for these patients. Different pathways producing different types of
oxidative stress occur in ESRD. The purpose of our study was to determine the effect of HD on plasma levels of
protein-bound dityrosine (di-Tyr), a biomarker of protein oxidation.
Methods: Protein-bounddi-Tyr formationwasmeasured by size exclusionHPLC coupled toﬂuorescence detector.
Clinical laboratory parameters were measured by standardized methods.
Results: Inmost ESRD patients, a single HD session decreased signiﬁcantly the plasma protein-bound di-Tyr level,
although the mean post-HD level remained signiﬁcantly greater than the one in healthy people. Furthermore,
pre-HD plasma protein-bound di-Tyr level was positively correlated with pre-HD serum creatinine and albumin
concentrations. No signiﬁcant correlation was found between plasma protein-bound di-Tyr level and serum
concentration of C-reactive protein, a biomarker of systemic inﬂammation.
Conclusions: This study demonstrates that a single HD session does not increase, rather partially decreases, oxi-
dative pathways producing di-Tyr in the haemodialyzed patient.
General signiﬁcance: The choice of the most pertinent biomarkers of oxidative stress is critical for the develop-
ment of novel treatments for ESRD. However, the relative importance of oxidative stress and inﬂammation in
ESRD remains largely undetermined, and several questions concerning oxidative stress and inﬂammation remain
poorly deﬁned. These results could stimulate further studies on the use of plasma protein-bound di-Tyr as a long-
lasting oxidative stress biomarker in ESRD.








Chronic kidney disease (CKD), or chronic renal failure, is an impor-
tant public health problem since its prevalence has reached epidemic
proportions, with 10–13% of the population affected in different coun-
tries around the world [1]. Patients affected by CKD are categorized
into ﬁve stages according to the glomerular ﬁltration rate and presence
of signs of kidney damage [2]. Compared with the general population,
CKD patients have a higher risk for premature death, primarily as a
result of cardiovascular disease (CVD), and their cardiovascular riskUniversity of Milan, via Celoria
. This is an open access article underincreases continuously with the decrease in kidney function [3]. Thus,
most patientswithmild tomoderate (stages 3–4) CKD die of CVD rather
than progress to end stage renal disease (ESRD, or CKD stage 5) [4].
ESRD represents the total inability of kidneys to maintain homeostasis
and hence is incompatible with life. Therefore, to ensure survival of
patients with ESRD, it is necessary to use methods that substitute for
kidney function, including haemodialysis (HD), peritoneal dialysis and
kidney transplantation. ESRD patients on maintenance HD too experi-
ence a higher risk for CVD and its associated mortality compared to
the general population [5].
Patients with CKD are at higher risk for CVD because of higher prev-
alence of traditional (such as age, diabetes mellitus, left ventricular
hypertrophy, dyslipidemia, hypertension) and non-traditional cardio-
vascular risk factors [6,7]. The latter include anaemia, uraemia, altered
calcium-phosphate metabolism, malnutrition, inﬂammation andthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 1
Characteristics of study group. Data are expressed as mean ± SE.
Haemodialyzed Patients
(n = 73)
Age (years) 69.62 ± 1.48
Sex 48 male, 25 female
Diabetes 50 nondiabetic, 23 diabetic
Length of time on dialysis (years) 5.71 ± 0.44
CRP (mg/dL) 0.51 ± 0.06
Albumin (g/dL) 3.50 ± 0.04
Fibrinogen(mg/dL) 355.47 ± 9.01
White blood cells (cells/mm3) 7293.15 ± 257.90
Haemoglobin (g/dL) 11.02 ± 0.11
Urea (mg/dL) 150.14 ± 4.76
Creatinine (mg/dL) 9.16 ± 0.35
56 G. Colombo et al. / BBA Clinical 7 (2017) 55–63oxidative stress [8–11]. In patients with ESRD, HD may also impose an
additional oxidative stress, mainly attributed to loss of circulating low-
molecular-mass dialyzable antioxidants and to the activation of neutro-
phil NADPH oxidase, provoking inﬂammation with release of reactive
oxygen species [11–14]. In fact, the extracorporeal treatment itself
represents a bioincompatible event in the patient's life: during the HD
session, blood is exposed 3 to 4 h to synthetic material, i.e., blood lines
and ﬁlter. Historically, the ﬁrst ﬁlters used in HD were composed of
cellulose: this treatment was so bioincompatible that patients used to
experience fever and chills during HD due to complement activation
[15]. Currently, with the use of synthetic ﬁlters, patients do not experi-
ence fever yet, but sub-clinical activation anddegranulation of polymor-
phonuclear neutrophils still occurs [16]. Moreover, intravenous iron
therapy in HD patients, even in recommended doses, could further
aggravate oxidative stress and atherosclerotic disease. Furthermore, in-
creased total body iron level exacerbates deﬁciency of lycopene and
other lipophilic antioxidants [17].
Four pathways producing different types of “oxidative” stress can be
hypothesized in CKD patients, i.e., classical oxidative stress, carbonyl
stress, nitrosative stress, and chlorine stress [18]. Increased oxidative
stress in patients with ESRD and CKD stage 3 or higher is demonstrated
by increase in plasma thiol-speciﬁc oxidative stress [19–23] and protein
carbonyls (PCO) [19,20,24–26] and by the presence of plasma advanced
oxidation protein products (AOPPs) [26–29].
AOPPs are considered as potential uremic toxins and inﬂammatory
mediators [30], involved in the activation of polymorphonuclear
granulocytes, monocytes and vascular endothelial cells [31,32]. Chronic
accumulation of AOPPs accelerates atherosclerosis by promoting oxida-
tive stress and inﬂammation [33]. Furthermore, AOPPs directly impair
metabolism of high-density lipoproteins, being potent antagonists of
their receptor and, therefore, might be directly involved in the develop-
ment of CVD [34].
AOPPs are a heterogeneous group of dityrosine (di-Tyr)1,
pentosidine and carbonyl-containing protein products generated in
plasma proteins by both myeloperoxidase (MPO)-dependent (e.g., in
ESRD patients) and MPO-independent (e.g., in the predialysis phase of
CKD) mechanisms during oxidative/chlorine stress [27,35]. AOPPs are
considered a generic biomarker of protein oxidation because their mo-
lecular composition has not yet been precisely deﬁned and their easy
spectrophotometric determination is often invalidated by poor repro-
ducibility and accuracy of most colorimetric methods for their detec-
tion. Furthermore, measuring AOPPs in diluted plasma as absorbance
at 340 nm is a rather nonselective way to determine the level of oxi-
dized proteins; therefore, it is necessary to take precautions tominimize
the contribution of species other than AOPPs. Consequently, reliable,
validated AOPP reference values in healthy humans are still lacking
[27,34–37]. In addition, measurement of AOPPs during HD session
gave contrasting results [20,38,39].
Our preliminary results showed a signiﬁcant (p b 0.001) increase in
di-Tyr ﬂuorescence (normalized to protein concentration) in plasma
samples of patients with ESRD undergoing regular maintenance HD as
compared to healthy controls [37]. As mentioned above, there is con-
cern that the HD session itself can be, at least in part, responsible of
this tremendous oxidative burden [38]. The purpose of the present
study was to determine the effect of a single HD session on plasma
levels of protein-bound di-Tyr, a biomarker of irreversible protein oxi-
dation, in ESRD patients onmaintenance HD.We also examined the po-
tential correlation between plasmaprotein-bounddi-Tyr concentration,
taken as a biomarker of oxidative stress and creatinine, albumin, and C-
reactive protein (CRP) concentration, taken as biomarkers of systemic
inﬂammation.1 In this manuscript the term dityrosine will refer to 3,3′-dityrosine (3,3′-bityrosine or
o,o′-dityrosine)2. Materials and methods
2.1. Study participants
All the patients enrolled in the study belong to stage 5 of CKDand are
referred to as ESRD patients. These patients do not show any residual
renal function and thus require renal replacement therapy. In addition
to hemodialysis, patients are treated with a pharmacological treatment
that varies upon the clinical necessities and consistsmainly on the treat-
ment of ESRD complications. Most of the patients assume drugs for
anaemia and bone mineral disorder. In particular, for anaemia they
may assume iron endovenous supplementation and/or erythropoietin,
and for bone mineral disorder calcium supplementation, phosphate
binders, vitamin D, paracalcitol and/or calcimimetics. In addition to
these therapies, patients may also take speciﬁc drugs for other comor-
bidities, e.g. hypertension, diabetes mellitus, ischemic cardiopathy and
other vasculopathies. Blood sampleswere collected after informedwrit-
ten consent from ESRD patients undergoingmaintenance HD at the Ne-
phrology Unit of the Humanitas Clinical and Research Center (Rozzano,
Milan, Italy). The samples have been collected at the arterial line at the
beginning and at the end of HD session. All theﬁlters usedweremade of
polyethersulphone (Polyﬂux™ Gambro-Baxter, Rome, Italy). The pres-
ence of a clinically evident infectious process was the only exclusion
criteria. For every patient an anamnestic record was collected. A de-
identiﬁcation of the samples was made for the further data treatment.
Seventy-three haemodialyzed patients joined the study (Table 1). Con-
trol blood sampleswere collected from 25 (13male and 12 female) age-
matched voluntary healthy donors at the Analysis Laboratory of the
University of Milan (Laboratorio Analisi Università di Milano), after
obtaining informed verbal consent. Criteria included no known history
of CKD or other diseases that could inﬂuence the analysis. In particular,
healthy subjects were tested for serum creatinine in order to exclude
CKD.
Sample collection
From ESRD patients, venous blood samples of 10 ml were collected
before HD and 5 ml were obtained after the same HD session. All sam-
ples were collected on the long inter-dialytic interval, i.e., two days
apart from thepreviousHD session. Bloodwas taken from the arteriove-
nous ﬁstula or central venous catheter. From healthy donors, 10 ml of
venous blood was collected from the antecubital vein. K3EDTA was
used as anticoagulant in all the blood samples. All the samples were
processed within the ﬁrst hour from blood sampling through centrifu-
gation for 10 min at 1000g, obtaining pre-HD and post-HD plasma ali-
quots from haemodialyzed patients and plasma aliquots from healthySodium (mmol/L) 137.80 ± 0.36
Potassium (mmol/L) 5.22 ± 0.09
Calcium (mmol/L) 2.23 ± 0.02
Phosphorus (mmol/L) 1.65 ± 0.05
Ferritin (ng/mL) 199.90 ± 16.03
Total iron-binding capacity (g/L) 184.62 ± 7.18
57G. Colombo et al. / BBA Clinical 7 (2017) 55–63controls. Such aliquots were stored at−80 °C until the execution of the
assays.2.3. Plasma protein-bound di-Tyr determination
Protein-bounddi-Tyr formationwas evaluated by Size Exclusion/Gel
Filtration High Performance Liquid Chromatography (GF-HPLC, same as
SE-HPLC) on a BioSep-SEC-S4000 column (300 mm × 7.8 mm) with a
guard column (SecurityGuard™ GFC-4000, 4 mm length × 3 mm ID)
and UV–VIS detector. Plasma samples were diluted 1:15 in 50 mM
Tris-HCl, pH 7.4 and 20 μl was loaded into the column for each sample.
The mobile phase consisted of Milli-Q water, containing 0.5% (w/v) SDS
andwas eluted at 1ml/min. Eluatesweremonitored both at 215 nm for
measuring absorbance of peptide bonds and at 415-nm emission with
325-nm excitation for measuring di-Tyr ﬂuorescence. In the time
range between 6 and 9 min, both the area under the 215-nm absor-
bance chromatogram (A215) and the area under the 415-nm emission
ﬂuorescence chromatogram (IF415nm em) were considered (Supplemen-
tary Fig. S1). The ratio between total ﬂuorescence and total absorbance
(IF415nm em/A215nm) was calculated for each sample.2.4. Determination of clinical laboratory parameters
CRP, white blood cells count, albumin, creatinine, ﬁbrinogen,
haemoglobin, ferritin, total iron-binding capacity, urea, sodium, potassi-
um, calcium, and phosphorus weremeasured by standardizedmethods
at the clinical laboratory of the Humanitas Clinical and Research Center.2.5. Statistical analysis
Student's t-test for independent samples was used to test for differ-
ences between the ESRD patients on maintenance HD and the age-
matched healthy subjects. The α-level of the tests was set at p b 0.05.
In Table 2, we reported the mean (standard error, SE) values estimated
on the largest sample available for each sex separately. Sex-speciﬁc
mean values were compared by independent-sample t-tests. The data
met the assumptions of homogeneity of within-sex variances (Levene's
test for homoscedasticity; F ≤ 1.52, p ≥ 0.22 for both markers) and of
within-sex normality (Kolmogorov-Smirnov test, Z ≤ 1.00, p ≥ 0.27 for
all sex-by-marker combinations). Analyses of covariance were used to
test for consistency of any sex-dependent variation in di-Tyr while con-
trolling for the potentially confounding effects of age. Predialysis (pre-
HD) and postdialysis (post-HD) di-Tyr values were compared by
Student's t-tests for paired samples within each sex separately. The re-
lationships between variables were investigated by linear regression
and Pearson's correlation coefﬁcient. Estimated parameters are present-
ed with their associate standard error (SE).Table 2
Plasma protein-bound di-Tyr content in male and female ESRD patients. Mean (SE) of
plasma protein-bound di-Tyr level in male and female ESRD patients before (pre-HD)
and after (post-HD) a single HD session. Sex-speciﬁcmeanvalueswere compared by inde-
pendent-sample t-tests.
N Mean (SE) t df P
di-Tyr pre-HD
Males 48 0.193 (0.005) 2.23 71 0.029
Females 25 0.170 (0.010)
di-Tyr post-HD
Males 47 0.174 (0.174) 2.11 70 0.039
Females 25 0.154 (0.010)3. Results
3.1. Plasma protein-bound di-Tyr levels in healthy people and ESRD
patients on maintenance HD
There are signiﬁcant differences in total plasma protein and albumin
concentrations between healthy subjects and patients with ESRD [23,
40], aswell as for each ESRD patient before and after a single HD session
[23]. The latter is due to ultraﬁltration performed during the dialysis
session in order to restore the dry body weight of the patient. This
deserves close consideration in the analysis of plasma protein-bound
di-Tyr concentrations, since any increase or decrease in total plasma
protein and albumin concentration can dramatically affect the di-Tyr
measured values. Therefore, in this study we express plasma protein-
bound di-Tyr content as IF415nm em/A215nm ratio.
Firstly, we determined the plasma protein-bound di-Tyr content in
healthy subjects and in ESRD patients before HD (Fig. 1). Plasma pro-
tein-bound di-Tyr content ranged from 0.064 to 0.116 IF415nm em/
A215nm (mean 0.084 ± 0.0024 IF415nm em/A215nm) in healthy subjects
(Fig. 1A) and from 0.109 to 0.324 IF415nm em/A215nm (mean 0.185 ±
0.0051 IF415nm em/A215nm) in ESRD patients before HD session (Fig.
1B), being signiﬁcantly higher in ESRD patients (t = 11.32, d.f. = 96,
p b 0.00001).
We evaluated the discriminative power of plasma protein-bound di-
Tyr content in distinguishing ESRD patients from age-matched healthy
subjects bymeans of receiver operating characteristic (ROC) curve anal-
ysis (Supplementary Fig. S2). Plasma protein-bound di-Tyr levels from
healthy subjects and ESRD patients yielded an area under the curve
(AUC) of 0.99 (95% conﬁdence interval 0.9943 to 1.002; p b 0.0001)
(Supplementary Fig. S2A). The cut-off level for plasma protein-bound
di-Tyr content as predictor of ESRDwas determined bymaximizing sen-
sitivity and speciﬁcity, at 0.112 IF415nm em/A215nm (Supplementary Fig.
S2B). Conversely, plasma protein-bound di-Tyr levels from diabetic
(n = 23) and non-diabetic (n = 50) ESRD patients yielded an AUC of
0.54 (not shown), implying that di-Tyr cannot discriminate between di-
abetic and non-diabetic ESRD patients.
3.2. Effect of a single HD session on the level of plasma protein-bound di-Tyr
To determine the effect of HD on the plasma protein-bound di-Tyr
level, we measured protein-bound di-Tyr in the plasma of the same
ESRD patients immediately before and immediately after a single HD
session. The scatter diagram of plasma protein-bound di-Tyr levels in
haemodialyzed patients is presented in Fig. 2A. In most ESRD patients,
we observed a small decrease in the plasma protein-bound di-Tyr
level after the HD procedure compared to the pre-HD value. Differently,
some ESRD patients showed the same or a slightly higher plasma pro-
tein-bound di-Tyr level immediately after the HD procedure compared
to the pre-HD value. The result of the Student's t-test for paired data
of plasma protein-bound di-Tyr level measured in ESRD patients pre-
HD (mean 0.185 ± 0.0051 IF415nm em/A215nm) and post-HD (mean
0.167 ± 0.0045 IF415nm emA215nm) proved that the means are signiﬁ-
cantly different (t = 7.11, d.f. = 71, p b 0.0001) (Fig. 2B). However,
this decrease did not result in normalization of plasma protein-bound
di-Tyr content that remained signiﬁcantly greater in ESRD patients
post-HD than in age-matched healthy subjects (mean 0.084 ± 0.0024
IF415nm em/A215nm) (Fig. 2B; see also Fig. 1A). It is worth noting that plas-
ma protein-bound di-Tyr level immediately before (pre-HD) and after
(post-HD) a single HD session differed between male and female
ESRD patients (Table 2). These results were conﬁrmed when we
checked for the potentially confounding effect of age on sex-dependent
variation in both pre-HD and post-HD plasma protein-bound di-Tyr
level in analyses of covariance,where agewas entered as a covariate (ef-
fect of sex on pre-HD and post-HD plasma protein-bound di-Tyr level:
F = 5.71, df = 1.70, p= 0.020 and F = 4.73, df = 1.69, p= 0.033, re-
spectively). Analyses of covariance revealed no signiﬁcant effect of age
Fig. 1. Plasma protein-bound di-Tyr level in healthy subjects and ESRD patients. (A) Plasma protein-bound di-Tyr in individual healthy subjects (n=25). (B) Plasma protein-bound di-Tyr
content in individual ESRD patients (n= 73) before HD session (pre-HD). In both (A) and (B), the horizontal solid and dashed lines represent, respectively, the mean and the SE of the
plasma protein-bound di-Tyr level.
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p ≥ 0.19). Simple linear regression analysis revealed that plasma pro-
tein-bound di-Tyr level measured pre-HD was signiﬁcantly positively
correlated with post-HD di-Tyr level in both male (Fig. 3A) and female
(Fig. 3B) ESRD patients (panel A: r = 0.884, p b 0.0001; panel B: r =
0.866, p b 0.0001).
3.3. Correlation between pre-HD serum creatinine and albumin concentra-
tions and plasma protein-bound di-Tyr level measured pre-HD
Haemodialyzed patients have b15–10% kidney functions and the se-
verely damaged kidneys do not efﬁciently remove creatinine from the
blood. Therefore, all ESRDpatients develop high serumcreatinine levels.
However, as a small molecule, creatinine is efﬁciently cleared by dialy-
sis. Thus, we examined the relationship between plasma protein-
bound di-Tyr level and predialysis creatinine concentration in ESRD
patients before a single HD session (Fig. 4). The scatter diagram of
predialysis serum creatinine concentration in individual ESRD patients
is presented in Fig. 4A Predialysis creatinine concentrations in ESRD pa-
tients ranged from 2.67 to 19.52 mg/dl (mean 9.1614 ± 0.3494 mg/dl)
(Fig. 4A) and were signiﬁcantly positively correlated with pre-HD plas-
ma protein-bound di-Tyr levels (Fig. 4B) (r= 0.318, p= 0.006).
The IF415nm em/A215nm ratio relative to total plasma proteins actually
mainly measures the di-Tyr content of albumin, because albumin is the
most abundant plasmaprotein, accounting for 50%–60% of total proteinsFig. 2. Effect of a single HD session on the level of plasma protein-bound di-Tyr. (A) Scatte
immediately before (black circles) and after (gray circles) a single HD session. (B) Plasma prot
HD) a single HD session. Data are expressed as mean ± SE. The horizontal solid and dashed lin
in age-matched healthy subjects (n= 25).in human plasma [41]. Therefore, we examined the relationship be-
tween plasmaprotein-bound di-Tyr content and albumin concentration
in ESRD patients before a single HD session (Fig. 5). The scatter diagram
of pre\\HDplasma albumin concentration in individual ESRDpatients is
presented in Fig. 5A. Predialysis albumin concentrations in ESRD pa-
tients ranged from 2.6 to 4.2 g/dl (mean 3.537 ± 0.0474 g/dl) (Fig.
5A) and were signiﬁcantly positively correlated with pre-HD plasma
protein-bound di-Tyr levels (Fig. 5B) (r= 0.315, p= 0.0055).
3.4. Correlation between pre-HD serum CRP concentration and plasma
protein-bound di-Tyr content measured pre-HD
Persistent inﬂammation is a prominent characteristic of patients
with ESRD, where it is a local process that is also reﬂected systemically
[42]. CRP, which is themost widely used inﬂammatory biomarker in the
clinical setting since high-sensitivity CRP assays are widely available
[43], is elevated up to ten-fold in haemodialyzed patients compared to
healthy individuals [44]. Hence, we investigated whether plasma pro-
tein-bound di-Tyr level was related to the serum CRP concentration in
ESRD patients before HD (Fig. 6). The scatter diagram shows that pre-
HD serum CRP concentration in ESRD patients ranged from 0.02 to
1.99 mg/dl (mean 0.515 ± 0.0609 mg/dl) (Fig. 6A). As shown in Fig.
6B, no correlation was found between plasma protein-bound di-Tyr
content and the serum CRP concentration in ESRD patients (r = 0.03;
p= 0.796).r diagram showing plasma protein-bound di-Tyr level in patients with ESRD (n = 73)
ein-bound di-Tyr content in ESRD patients immediately before (pre-HD) and after (post-
es represent, respectively, the mean and the SE of the plasma protein-bound di-Tyr level
Fig. 3. Correlations between plasma protein-bound di-Tyr levels in ESRD patients (n= 73) measured immediately before (pre-HD) and after (post-HD) a single HD session. (A) Males
(n= 48), (B) females (n= 25). Correlations were investigated using simple linear regression analysis.
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The accessibility of plasma proteins for sampling, the relatively long
half-lives of many plasma proteins, and the well-characterized bio-
chemical pathways of protein oxidation make plasma proteins an
attractive biomarker of oxidative stress in ESRD patients on HD. Bio-
markers of protein oxidation can be classiﬁed in two types: (i) generic
biomarkers,which include oxidation ofmultiple residueswithin protein
to form several products, e.g., PCO and AOPPs [37,45]; and (ii) speciﬁc
biomarkers, which are very speciﬁc in both the residue oxidized and
the product generated: e.g., oxidation of protein free sulphydryl groups
(P-SH) and oxidation of protein Tyr residues to give di-tyrosines [46].
Single HD sessions have different effects on the different types of
biomarkers of protein oxidation. For example, in haemodialyzed
patients plasma protein oxidation is revealed by decreased P-SH [23],
which might result from S-thiolation, the formation of mixed
disulphides between P-SH and low-molecular-mass aminothiols,
which is considered to be the mechanism protecting P-SH from losing
their biological activity by irreversible oxidation [47,48]. S-thiolated
plasma proteins are indeed increased in haemodialyzed patients [21–
23,40]. However, a single HD session, by removing solutes responsible
for increasing ROS production and the low-molecular-mass aminothiols
involved in S-thiolation [21], caused transient return of plasma P-SH to
the level equal or close to that occurring in healthy subjects [20,21,23].
De-thiolation of S-thiolated proteins during a single HD session can be
explained by considering the reversible reactions involved in S-
thiolation [47]. This is very important in the case of albumin, because
its Cys34 thiol represents the largest fraction of all free thiols in plasma,Fig. 4. Correlation between pre-HD serum creatinine concentration and pre-HD plasma protei
ESRD patients (n = 73) before HD session (pre-HD). The horizontal solid and dashed lines r
Positive linear correlation between serum creatinine concentration and plasma protein-boundthus attributing to albumin a major role in total plasma antioxidant ca-
pacity [41]. Serum albumin de-thiolation during a single HD session
may restore transiently its antioxidant activity in haemodialyzed pa-
tients [49]. Therefore, S-thiolated proteins represent a useful indicator
of thiol-speciﬁc reversible oxidative stress in ESRD patients on HD.
Otherwise, by measuring plasma PCO after reaction with 2,4-
dinitrophenylhydrazine (DNPH), a number of studies have demonstrat-
ed that plasma PCO concentrations increase in ESRD patients [19,20,24,
25]. Detection and quantiﬁcation of PCO by means of DNPH-based
methods does not allow for any distinction between primary, or direct,
and secondary, or indirect, protein carbonylation [46,50] and also mea-
sure sulphenic acids [51]. Therefore, PCO provide a general and widely
used biomarker of severe protein oxidation in ESRD patients.
Increased oxidative stress in ESRD patients is also revealed by the
formation of plasmaAOPPs [27–29], which are considered a generic bio-
marker of protein oxidation and oxidative stress. In this respect, deter-
mination of protein-bound di-Tyr by GF-HPLC with ﬂuorometric
detection could be taken as a highly speciﬁc biomarker of protein oxida-
tion [23,52–54]. Protein-bound di-Tyr are ﬁnal, chemically stable and
easily detectable products of tyrosine oxidation in response to oxidative
stress induced by both non-enzymatic and peroxidase-catalyzedmech-
anisms [52,55]. Myeloperoxidase (MPO), a haemoprotein present in
phagocytes, uses hydrogen peroxide to generate di-Tyr from Tyr resi-
dues via its peroxidase cycle, in amanner that functionsmost efﬁciently
at neutral to slightly alkaline pH (7.5–8), near the physiological concen-
trations of chloride ions and amino acids [56]. In haemodialyzed pa-
tients, plasma levels of MPO are signiﬁcantly higher than the reference
value for healthy subjects and further increase during HD [38,57].n-bound di-Tyr level in ESRD patients. (A) Serum creatinine concentrations in individual
epresent, respectively, the mean and the SE of the serum creatinine concentration. (B)
di-Tyr level pre-HD in ESRD patients (n= 73).
Fig. 5. Correlation between pre-HD plasma albumin concentration and pre-HD plasma protein-bound di-Tyr level in ESRD patients. (A) Plasma albumin concentrations in individual ESRD
patients (n = 73) before HD (pre-HD). The horizontal solid and dashed lines represent, respectively, the mean and the SD of the plasma albumin concentration. (B) Positive linear
correlation between plasma albumin concentration and plasma protein-bound di-Tyr content pre-HD in ESRD patients (n= 73).
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degree of oxidative stress induced usingdialysismembranes of different
biocompatibilities [38]. Increased MPO activity could also serve as one
mechanistic link between inﬂammation, oxidative stress and endotheli-
al dysfunction in ESRD [58] andwas found to be associatedwithmortal-
ity in ESRD patients undergoing HD [18,59].
We found signiﬁcantly higher pre-HD levels of plasma protein-
bound di-Tyr in haemodialyzed patients compared with di-Tyr level in
age-matched healthy subjects (Fig. 1). The AUC (0.99) indicates that
the ROC curve has excellent accuracy and that plasma protein-bound
di-Tyr level is good indicator of ESRD due to its high sensitivity and
speciﬁcity in discriminating between ESRD patients and age-matched
healthy subjects (Supplementary Fig. S2). However, the usefulness of
plasma protein-bound di-Tyr level in clinical practice is questionable,
as there is no need for a new biomarker to dignose ESRD. Rather, the in-
teresting ﬁnding is that, in most ESRD patients, a single HD session de-
creased signiﬁcantly the plasma protein-bound di-Tyr level, even if
the mean level of plasma protein-bound di-Tyr post-HD remained sig-
niﬁcantly greater in ESRD patients compared to the mean di-Tyr level
in age-matched healthy subjects (Fig. 2). Conversely, in a previous
study, AOPPs increased during dialysis session, both in patients using
a cellulose ﬁlter and in patients using polysulphone ﬁlters, the latters
being the ﬁlters also used in our group of patients [38]. In two other
studies, a single HD session had no effect on AOPP concentration,
which remained signiﬁcantly greater than normal after the HD session
[20,39]. Given that di-Tyr is a more speciﬁc biomarker of protein oxida-
tion and oxidative stress than AOPPs [52,55], our data challenge theFig. 6. Correlation between pre-HD serumCRP concentration and pre-HDplasma protein-bound
(n= 73) before HD (pre-HD). (B) Relationship between serum CRP concentration and plasmaprevious ﬁndings, suggesting that, in general, the HD session itself
does not make the patient's oxidative status worse and can even im-
prove it. It is worthy to note that, in our patients, creatinine levels
were correlated with pre-HD plasma protein-bound di-Tyr levels (Fig.
4). Although creatinine is inﬂuenced by leanbodymass in ESRDpatients
onHD [60], it is one of the historically used biomarkers of uraemia inHD
and its levels efﬁciently predict mortality in this population [61,62].
Thus, creatinine is a faithful biomarker of uraemia that, on turn, is
known to affect deeply the oxidative status of the patient: this explains
the good correlation thatwe found between di-Tyr levels and creatinine
concentration before dialysis. Therefore, we can speculate that the oxi-
dative damage due to uraemic toxins is efﬁciently improved by the
HD session, as demonstrated by reduction of protein-bound di-Tyr. On
the other hand, AOPPs may represent a grosser marker of oxidative
stress that, in HD patients, is also due the presence of comorbidities,
such as diabetes mellitus, and the occurrence of acute clinical events,
such as infections. However, future studieswith a greater number of pa-
tients, inclusive of patients with CKD stages 1–5, are needed to extend
these ﬁndings, because the usefulness of the ideal biomarker of oxida-
tive damage lies in its ability to provide early indication of disease
and/or its progression. As we expected, plasma protein-bound di-Tyr
levels measured pre-HD were signiﬁcantly positively correlated with
post-HD plasma protein-bound di-Tyr levels (Fig. 3).
We also found amoderate positive correlation between plasma pro-
tein-bound di-Tyr level and pre-dialysis serum albumin concentration
(Fig. 5). This result is particularly interesting considering that serum al-
bumin, which is frequently considered a predictor of nutritional statusdi-Tyr content in ESRDpatients. (A) SerumCRP concentrations in individual ESRDpatients
protein-bound di-Tyr level pre-HD in ESRD patients (n= 73).
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hypoalbuminaemia is associated with mortality in haemodialyzed pa-
tients [64–67]. However, other studies suggest that hypoalbuminaemia
may be more reﬂective of inﬂammation than nutritional status in ESRD
patients [58,68–70]. In addition, a linkage of hypoalbuminaemia, in-
ﬂammation, and oxidative stress has been shown in ESRD patients re-
ceiving maintenance HD therapy. Indeed, there is a high prevalence of
inﬂammation and oxidative stress in these patients and levels of inﬂam-
matory and oxidative stress biomarkers are increased further in hypoal-
buminaemic compared with normoalbuminaemic haemodialyzed
patients [71]. Therefore, we hypothesized that plasma protein-bound
di-Tyr level could correlate with circulating inﬂammatory biomarkers.
Among the variety of circulating inﬂammatory biomarkers, CRP, the
major acute phase response protein, is elevated in ESRD patients and is
themostwidely used inﬂammatorymarker predicting future cardiovas-
cular risk and mortality in ESRD patients [42,72–74]. In contrast to our
hypothesis, the results do not show any statistically signiﬁcant correla-
tion between plasma protein-bound di-Tyr level and serum concentra-
tion of CRP (Fig. 6). These results are in line with others showing no
correlations between plasma AOPPs and CRP [28,75]. Anyway, these re-
sults are somewhat surprising considering that inﬂammation, which is
not conﬁned to the kidney, rather it is systemic [76–78], is a common
feature of ESRD patients and both oxidative stress and inﬂammation
are usually inseparably linked and participate in a self-perpetuating
vicious circuit. Consequently, the presence and severity of systemic
inﬂammation contribute to ESRD-associated oxidative stress. Indeed,
there is evidence to suggest that renal transplantation is associated
with almost complete correction of the biomarkers of oxidative stress
(measured as PCO) and inﬂammation (measured as CRP) in patients
with ESRD [79,80]. Thus, our results could suggest that, in
haemodialyzed patients, oxidative stress and inﬂammation may also
be in part independent of each other. Otherwise, the absence of correla-
tion between plasma protein-bound di-Tyr level and CRP concentration
(measured as “pinpoint marker”) could be explained by the fact that
CRP concentration ﬂuctuates substantially over time in patients under-
going HD; therefore, reliable CRP levels can be obtained following regu-
lar, repeated measurements [74].
This study has strengths and limitations. Strengths include, ﬁrstly,
the use of a highly speciﬁc biomarker of protein oxidation easy to
detect: the intrinsic ﬂuorescence properties of di-Tyr and its chemical
stability (fairly unreactive to changes in oxygen and/or pH) allow for
its sensitive detection in proteins [23,52–55]. Furthermore, plasma
protein-bound di-Tyr are obviously not washed out during HD
session, unlike some small molecules, such as 4-hydroxynonenal,
malonyldialdehyde, and free F2-isoprostanes, which were considered
promising biomarkers of oxidative stress in ESRD patients [81–83]),
which are washed out during HD session. In addition, if we consider
that protein-bound di-Tyr are carried mainly by albumin in the blood
and that albumin half-life in plasma is ~19 days [84], protein-bound
di-Tyr might serve as long-lasting biomarkers of oxidative stress in
ESRD patients. The ﬁnding that di-Tyr levels decreased at the end of
the dialysis session has to be further discussed, since di-Tyr represents
an irreversible oxidative product and, of course, dialysis cannot modify
it. However,modern dialyzers have an increasedmolecular cut-off com-
pared to the older ones, and are capable to dialyze lowmolecularweigth
proteins, such as beta-2microglobulin, which has amolecular weigth of
11.8 kD and six Tyr residues. Given that we assessed di-Tyr levels as the
ratio to total serum proteins, we can speculate that the dialysis of low
molecular weigth proteins richer in di-Tyr could have improved the
overall content of di-Tyr at the endof the dialysis session. This, of course,
does not imply that the di-Tyr content of larger proteins that are not di-
alyzed, such as albumin, has been modiﬁed by the dialysis session. Lim-
itations include the relatively small number of ESRD patients, the fact
that the study has been performed in only one single HD centre, and
measurements have been made at single time points (“pinpoint mark-
er”). Another limitation is that we assessed the effect of a single HDsession using only a single ﬁlter type: it would be interesting, in the fu-
ture, to analyze the inﬂuence of different type of dialyzers on plasma
protein-bound di-Tyr levels. We thus consider our ﬁndings as hypothe-
sis-generating and hope that these results stimulate further studies on
the use of plasma protein-bound di-Tyr as a biomarker for oxidative
stress in ESRD,with a larger number of haemodialyzed patients enrolled
from different dialysis centres.
In conclusion, the choice/indication of the most pertinent bio-
markers of oxidative stress is a critical step in the development of
novel treatment options for ESRD patients. Furthermore, ESRD is associ-
ated with other pro-oxidant conditions such as CVD and diabetes
mellitus. In this regard, the relative importance of the different types
of oxidative stress and inﬂammation in ESRD remains largely undeter-
mined, and several questions concerning oxidative stress and inﬂam-
mation remain poorly deﬁned. Additional large-scale studies with the
inclusion of clinically relevant endpoints are required to examine the
potential correlations between a panel of biomarkers of inﬂammation
and oxidative stress in ESRD patients on HD. This may pave the way
for potential therapeutic intervention aimed at reducing the oxidative
stress in hemodialysed patients. The widespread use of anti-oxidants
cannot be recommended yet, as large studies with hard end-points are
currently lacking. However, when taking into account some surrogate
end-points, such as albumin for malnutrition, the already available
data are encouraging [85]. Moreover, the use of more biocompatible
and anti-oxidant ﬁlters, such as vitamin E-coated polysulfone
membranes, could potentially change the clinical practice in the future
[86,87].
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